Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 121

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 121
---
, lessee, supplier, distributor, 
 agent or customer of the Company;                                                                                                                                                                                                                     |

| (ii) | owns, directly or indirectly, in whole or in part, any property that the Company uses or intends to use in the 
 operation of its business; or                                                                                  |

| (iii) | has any cause of action or other claim whatsoever against, or owes any amount to, the Company, except for any 
 liabilities reflected in the Financial Statements and claims for accrued vacation pay and accrued benefits.   |

| 23. | No Insolvency Proceedings |

No act or proceeding has been taken by or against the Company or its Subsidiary in connection with the dissolution, liquidation, winding up, bankruptcy or reorganization of the Company or its Subsidiary or for the appointment of a trustee, receiver, manager or other administrator of the Company or its Subsidiary or any of their properties or assets nor, to the knowledge of the Company, is any such act or proceeding threatened. The Company and its Subsidiary have not sought protection under the Bankruptcy and Insolvency Act(Canada), the Companies’ Creditors Arrangement Act(Canada) or similar legislation. Neither the Company, its Subsidiary nor any of their respective properties or assets are subject to any outstanding judgment, order, writ, injunction or decree that involves or may involve, or restricts or may restrict, the right or ability of the Company or its Subsidiary to conduct the Discontinuance in all material respects as it has been carried on prior to the date hereof, or that has had or would reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change or to prevent or significantly impede or materially delay the completion of the Contemplated Transactions.

| 24. | No Material Change |

Since September 30, 2025, except in connection with the Discontinuance, no change has occurred in any of the assets, business, financial condition or results of operations of the Company which, individually or in the aggregate, has had, will have or could reasonably be expected to result in a Material Adverse Change.

| 25. | Authorizations |

The Company and its Subsidiary possess all Authorizations necessary to properly conduct their respective businesses, except for any such Authorizations, the failure of which to possess, individually or in the aggregate, E-11

would not reasonably be expected to result in a Material Adverse Change or would